Monoclonal antibody treatments have many challenges — Narval is fixing them

2017-08-24_00h03_35 IT総合
Monoclonal antibodies are the building blocks of some of the most important medical treatments in the world. But they have limitations. For example, the large size of the molecules mean monoclonal antibody treatments usually need to be injected — even for eye conditions. Narval CEO Jose Luis Nuno describes the first time he saw a […]
Source: TCじゃぱん

リンク元

コメント

タイトルとURLをコピーしました